Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-viral Multi-targeted CAR-T in Advanced Solid Tumors
NCT06327997Phase 1Recruiting
- Sponsor
- Shanghai Cell Therapy Group
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BZT-2312 in solid tumor, sponsored by Shanghai Cell Therapy Group. Primary endpoint: Dose-limiting toxicity at 28 days. Started Mar 2024; status: recruiting.
02
Drugs
BZT-2312
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06327997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327997.